Rezolute to present Phase 2 RIZE overnight hypoglycemia data at PES Annual Meeting

Rezolute, Inc.

Dr. Paul Thornton will present poster analyzing overnight hypoglycemia in congenital HI patients on May 4, 2024 at PES meeting.
Sub-analyses from Phase 2 RIZE study highlight RZ358 benefits during overnight fasting using CGM metrics.
Previously reported results showed up to ~90% reduction in hypoglycemia events and time at top doses.
Phase 3 study of RZ358 for congenital hyperinsulinism is currently underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.